Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism.

George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA

Clinical endocrinology19 Apr 2013Cited by 84 (Europe PMC)

PMID23153270DOI10.1111/cen.12103PepBankPUB-23153270

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
The LH increase after a kisspeptin‑10 bolus was comparable in men with type 2 diabetes and healthy men.
In plain wordsThe LH rise after a kisspeptin‑10 injection was similar in men with type 2 diabetes and in healthy men.
Peptide
Kisspeptin-10
Outcome
No significant changeLH increase (ΔLH) after bolus, T2DM vs healthy men
Study
n = 12
Comparator
Healthy men
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.3 mcg/kg bolus · intravenousAs given in this study (human).
Source sentences
Summary
EXPERIMENT 1: Mean LH increased in response to intravenous administration of kisspeptin-10 (0·3 mcg/kg bolus) both in healthy men (5·5 ± 0·8 to 13·9 ± 1·7 IU/l P < 0·001) and in men with T2DM (4·7 ± 0·7 to 10·7 ± 1·2 IU/l P = 0·02) with comparable ΔLH (P = 0·18).
1 context sentence(design, population, supporting numbers)
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327003
02HumanNon-randomized trialEfficacy outcome
In healthy men, an intravenous kisspeptin‑10 bolus increased mean LH.
In plain wordsIn healthy men, a kisspeptin‑10 injection raised blood LH.
Peptide
Kisspeptin-10
Outcome
IncreaseMean LH after bolus kisspeptin-10, healthy men
Study
n = 7
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.3 mcg/kg bolus · intravenousAs given in this study (human).
Source sentences
Summary
EXPERIMENT 1: Mean LH increased in response to intravenous administration of kisspeptin-10 (0·3 mcg/kg bolus) both in healthy men (5·5 ± 0·8 to 13·9 ± 1·7 IU/l P < 0·001) and in men with T2DM (4·7 ± 0·7 to 10·7 ± 1·2 IU/l P = 0·02) with comparable ΔLH (P = 0·18).
1 context sentence(design, population, supporting numbers)
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327001
03HumanNon-randomized trialEfficacy outcome
In hypotestosteronaemic men with type 2 diabetes, an intravenous kisspeptin‑10 bolus increased mean LH.
In plain wordsIn men with type 2 diabetes and low testosterone, a kisspeptin‑10 injection raised blood LH.
Peptide
Kisspeptin-10
Outcome
IncreaseMean LH after bolus kisspeptin-10, men with T2DM
Study
n = 5
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.3 mcg/kg bolus · intravenousAs given in this study (human).
Source sentences
Summary
EXPERIMENT 1: Mean LH increased in response to intravenous administration of kisspeptin-10 (0·3 mcg/kg bolus) both in healthy men (5·5 ± 0·8 to 13·9 ± 1·7 IU/l P < 0·001) and in men with T2DM (4·7 ± 0·7 to 10·7 ± 1·2 IU/l P = 0·02) with comparable ΔLH (P = 0·18).
1 context sentence(design, population, supporting numbers)
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327002
04HumanNon-randomized trialEfficacy outcome
In hypotestosteronaemic men with type 2 diabetes, an 11 h intravenous kisspeptin‑10 infusion increased LH.
In plain wordsIn men with type 2 diabetes and low testosterone, an 11 hour kisspeptin‑10 infusion raised blood LH.
Peptide
Kisspeptin-10
Outcome
IncreaseMean LH during 11 h kisspeptin-10 infusion
Study
n = 4
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
4 mcg/kg/h · intravenous · 11 hAs given in this study (human).
Source sentences
Summary
There were increases in LH (3·9 ± 0·1 IU/l to 20·7 ± 1·1 IU/l P = 0·03)
2 context sentences(design, population, supporting numbers)
Summary · context
An intravenous infusion of kisspeptin-10 (4 mcg/kg/h) was administered for 11 h, 5 days later.
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327004
05HumanNon-randomized trialEfficacy outcome
In hypotestosteronaemic men with type 2 diabetes, an 11 h intravenous kisspeptin‑10 infusion increased serum testosterone.
In plain wordsIn men with type 2 diabetes and low testosterone, an 11 hour kisspeptin‑10 infusion raised blood testosterone.
Peptide
Kisspeptin-10
Outcome
IncreaseSerum testosterone during 11 h kisspeptin-10 infusion
Study
n = 4
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
4 mcg/kg/h · intravenous · 11 hAs given in this study (human).
Source sentences
Summary
testosterone (8·5 ± 1·0 to 11·4 ± 0·9 nmol/l, P = 0·002).
2 context sentences(design, population, supporting numbers)
Summary · context
An intravenous infusion of kisspeptin-10 (4 mcg/kg/h) was administered for 11 h, 5 days later.
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327005
06HumanNon-randomized trialEfficacy outcome
In hypotestosteronaemic men with type 2 diabetes, kisspeptin‑10 infusion increased LH pulse frequency.
In plain wordsIn men with type 2 diabetes and low testosterone, kisspeptin‑10 infusion made LH pulses more frequent.
Peptide
Kisspeptin-10
Outcome
IncreaseLH pulse frequency during kisspeptin-10 infusion
Study
n = 4
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
4 mcg/kg/h · intravenous · 11 hAs given in this study (human).
Source sentences
Summary
LH pulse frequency increased from 0·6 ± 0·1 to 0·9 ± 0 pulses/h (P = 0·05)
2 context sentences(design, population, supporting numbers)
Summary · context
An intravenous infusion of kisspeptin-10 (4 mcg/kg/h) was administered for 11 h, 5 days later.
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327006
07HumanNon-randomized trialEfficacy outcome
In hypotestosteronaemic men with type 2 diabetes, kisspeptin‑10 infusion increased the pulsatile component of LH secretion.
In plain wordsIn men with type 2 diabetes and low testosterone, kisspeptin‑10 infusion raised the pulsing part of LH release.
Peptide
Kisspeptin-10
Outcome
IncreasePulsatile component of LH secretion during kisspeptin-10 infusion
Study
n = 4
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
4 mcg/kg/h · intravenous · 11 hAs given in this study (human).
Source sentences
Summary
pulsatile component of LH secretion from 32·1 ± 8·0 IU/l to 140·2 ± 23·0 IU/l (P = 0·007).
2 context sentences(design, population, supporting numbers)
Summary · context
An intravenous infusion of kisspeptin-10 (4 mcg/kg/h) was administered for 11 h, 5 days later.
Summary · context
Five hypotestosteronaemic men with T2DM (age 33·6 ± 3 years, BMI 40·6 ± 6·3, total testosterone 8·5 ± 1·0 nmol/l, LH 4·7 ± 0·7 IU/l, HbA1c 7·4±2%, duration of diabetes <5 years) and seven age-matched healthy men.
Report a problemFND-2315327007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.